Medsafe Aware of Weight Loss Drug Concerns

Tuesday, December 8th 2009

New Zealand medicines regulator Medsafe says it is aware of international concerns about weight-loss drug Reductil and is reviewing the risks.

Group manager Stewart Jessamine said Medsafe would take into account study data referred to the United States Food and Drug Administration (FDA) which suggests those taking Reductil (sibutramine) could be at increased risk of heart problems.

It was now waiting on more information from the drug's US manufacturer, including the study data, before taking any further action.

"Medsafe will provide further advice to healthcare professionals and consumers as necessary," Dr Jessamine said.

"In the meantime, health care professionals are reminded to avoid using sibutramine in patients with a history of coronary artery disease, congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmia, or stroke, as recommended in the sibutramine data sheet."

He urged patients to report any suspected adverse reactions to their doctor.

Source: stuff.co.nz NZPA 4th December 2009

Footnote from Leanne James:  We were very concerned to read of this, as we know of young people who have been prescribed this by their GP. 1 lady ended up in hospital after suffering a heart attack. She was in her 20s. The hospital denied that it had anything to do with this drug, although when we checked on medsafes website, we saw that the problems she experienced were listed as known adverse reactions. 

There are many safer alternatives to drugs like this. 

To find out more about some of the supplements we have for helping with more effective fat loss, watch this video where Leanne talks about some that she stocks on healthyonline.

http://blog.healthy.co.nz/what-is-healthy-weight-loss/